Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
Autor:
Mark A Marinella
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1482-1485
The ongoing pandemic caused by severe acute respiratory syndrome (SARS) coronavirus type 2 (SARS-CoV-2, also known as COVID-19) has caused unprecedented strain on the global healthcare system, causing thousands of deaths worldwide. Patients with unde
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:286-292
Background National guidelines recommend screening and treatment for cancer-related bone disease and continued monitoring of bone-modifying agents. It is unclear whether a standardized screening tool is utilized to identify eligible patients and ensu
Autor:
Faisal Inayat, Nouman Safdar Ali, Hilal Hachem, Muhammad Haseeb Aslam, Aishatu Aloma, Muhammad Wasif Saif, Fei Song
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1500-1508
Patients undergoing cytotoxic or immunosuppressive therapy for cancer have an established predilection for hepatitis B virus reactivation; however, the risk associated with newer molecularly targeted agents has not been well investigated. Imatinib, a
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:261-268
Background Direct oral anticoagulants (DOACs) are not recommended for venous thromboembolism (VTE) treatment in patients with cancer because their safety and efficacy have not been compared to low molecular weight heparin (LMWH) in large trials. Rout